ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0525

Cost-of-Illness Among Newly Diagnosed Patients with Psoriatic Arthritis in Sweden
Abstract Number: 2228

COVID-19 Outcomes in Rheumatoid Arthritis Patients Prescribed Biologic vs. Conventional DMARDs: A Propensity-Matched Analysis
Abstract Number: 1737

CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype
Abstract Number: 0218

Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Abstract Number: 0315

Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Abstract Number: 2604

Cross-Sectional Relationship Between Sarcopenic Obesity and Knee Osteoarthritis: The Johnston County Osteoarthritis Project
Abstract Number: 0907

Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
Abstract Number: 0208

Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
Abstract Number: 0720

Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
Abstract Number: 2477

Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Abstract Number: 1878

Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
Abstract Number: 1207

Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Abstract Number: 2699

Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
Abstract Number: 2409

Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Abstract Number: 1912

Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].